Antiangiogenic therapy with interferon alpha for giant cell lesions of the jaws

Kaban, Leonard B.; Troulis, Maria J.; Ebb, David H.; August, Meredith; Hornicek, Francis J.; Dodson, Thomas B.

doi:10.1053/joms.2002.34975

Cited by 190 publications

(140 citation statements)

References 41 publications

Supporting

Mentioning

123

Contrasting

Unclassified

Order By: Relevance

“…The local recurrence rate was 4.2% in patients treated with bisphosphonate and 30% in a control group 16 . Combined treatment followed by administration of interferon alfa resulted in a high rate of gctb control and reduced surgical morbidity 17 . Based on the therapeutic effect up to 6 years, it has also been supposed that there is a role for interferon in chemotherapyrefractory gctb 18 .…”

Section: Introductionmentioning

confidence: 99%

Denosumab and Giant Cell Tumour of Bone—A Review and Future Management Considerations

Xu¹,

Adams

Yu³

et al. 2013

Current Oncology

View full text Add to dashboard Cite

specimen revealed a tumour mass with histologic features of pronounced osteogenesis and no more evidence of gctb. This case demonstrated a major tumour response to denosumab in the neoadjuvant setting, with a complete pathologic response.Is denosumab a breakthrough in the treatment of gctb? We reviewed the literature focusing on denosumab and gctb, and here we discuss the biggest questions related to the future management of gctb. GIANT CELL TUMOUR OF BONEAs one type of giant-cell-rich lesion of bone, gctb is characterized by the presence of numerous multinucleated osteoclast-type giant cells, and in this mesenchymal tumour, the mononuclear stromal cells are the neoplastic cell type 2 . The giant cells have been confirmed to express rankl and are responsible for the aggressive osteolytic nature of the tumour 3 . Although generally benign, atypical gctb may be associated with multiple local recurrences, multicentricity, pulmonary metastases, or lesions that cannot be removed surgically without causing substantial morbidity 4 . The World Health Organization therefore classifies gctb as "an aggressive, potentially malignant lesion" 5 .In the United States, gctb accounts for approximately 5% of all primary bone tumours and 20% of all benign bone tumours in adults 6 . About 50−60 new cases of gctb are managed by specialist health care services each year in the United Kingdom 7 . The disease is more common in China and India, where it constitutes approximately 20% of all primary bone tumours 5 . Giant cell tumour of bone occurs most commonly during the second to fourth decades of life (60%-75%) and has a maleto-female ratio in the range 1:1.2 to 1:1.5 2,5 . Most lesions develop in the long bones (75%-90%), with most cases (50%-65%) occurring near the knee 1,2,8 . Other frequent sites are the distal radius, proximal humerus, fibula, sacrum, and vertebral body (fewer than 3% of cases) 2,8 . In no reported case has gctb ABSTRACT Giant cell tumour of bone (gctb) is one type of giantcell-rich bone lesion characterized by the presence of numerous multinucleated osteoclast-type giant cells. Giant cells are known to express rankl (receptor activator of nuclear factor κB ligand) and are responsible for the aggressive osteolytic nature of the tumour. No available treatment option is definitively effective in curing this disease, especially in surgically unsalvageable cases. In recent years, several studies of denosumab in patients with advanced or unresectable gctb have shown objective changes in tumour composition, reduced bony destruction, and clinical benefit.Denosumab is a fully human monoclonal antibody that targets and binds with high affinity and specificity to rankl. Several large phase iii studies have shown that denosumab is more effective than bisphosphonates in reducing skeletal morbidity arising from a wide range of tumours and that it can delay bone metastasis. The relevant articles are reviewed here. The controversies related to the future use of denosumab in the treatment of gctb are discussed. KEY WORDSDenosuma...

show abstract

Section: Introductionmentioning

confidence: 99%

Denosumab and Giant Cell Tumour of Bone—A Review and Future Management Considerations

Xu¹,

Adams

Yu³

et al. 2013

Current Oncology

View full text Add to dashboard Cite

show abstract

“…10,38 In the literature, the recurrence rates of CGCG ranges from 11.0% to 49.0% or higher, depending on the type and/or treatment. 2,4,5,8,23,[39][40][41] Consequently, , we could not find any case knowledge in the literature about the etiopathogenesis of patients with multifocal CGCG not associated with systemic disorders or syndromes in the jaws. In presented case, local trauma caused by dental prosthesis could be a probable etiologic factor.…”

Section: Discussionmentioning

confidence: 91%

Multifocal Central Giant Cell Granuloma of the Jaws: Case Report and Review of Literature

Kılınç¹,

Saruhan²,

Ertaş³

et al. 2015

Turkiye Klinikleri J Dental Sci Cases

View full text Add to dashboard Cite

C entral giant cell granuloma (CGCG) is a relatively rare nonneoplastic, intraosseus lesion first described by Jaffe in 1953, and it accounts for less than 7% of all benign maxillofacial bone lesions.1 CGCG occurs more often in the mandible than in the maxilla, affects females more than males, and is commonly seen in individuals under the age of 30. The clinical behavior of CGCG varies and ranges from a slowly growing asymptomatic swelling to a tender aggressive lesion that causes local bone lysis, pain, root resorption, and displacement of teeth.

show abstract

“…Nonsurgical approaches like chemical cautery, electrocautery, cryotherapy have been used and newer therapies like calcitonin, interferon alpha and intralesional steroids are being used to avoid disfigurement. [26][27][28][29][30] …”

Section: Discussionmentioning

confidence: 99%

Central Giant Cell Granuloma of the Jaws: A Short Series and Review of Literature

Mathur¹,

Kundu²,

Mohan³

et al. 2011

World Journal of Dentistry

View full text Add to dashboard Cite

show abstract

Antiangiogenic therapy with interferon alpha for giant cell lesions of the jaws

Cited by 190 publications

References 41 publications

Denosumab and Giant Cell Tumour of Bone—A Review and Future Management Considerations

Denosumab and Giant Cell Tumour of Bone—A Review and Future Management Considerations

Multifocal Central Giant Cell Granuloma of the Jaws: Case Report and Review of Literature

Central Giant Cell Granuloma of the Jaws: A Short Series and Review of Literature

Contact Info

Product

Resources

About